Business
Nektar Therapeutics to Host Virtual Investor & Analyst Event with Dermatology Experts on September 13th
SAN FRANCISCO, Sept. 6, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that it will host a virtual investor and analyst event on
About this update from Nektar Therapeutics
[{"type":"text","content":"SAN FRANCISCO, Sept. 6, 2023 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced that it will host a virtual investor and analyst event on Wednesday, September 13, 2023 at 11:00 a.m. EST / 8:00 a.m. PST to discuss the final Phase 1b data of rezpegaldesleukin (REZPEG) in patients with atopic dermatitis, the atopic dermatitis treatment landscape, and the potential role of REZPEG, Nektar's novel, first-in-class selective regulatory T-cell (Treg) therapy, in the treatment of atopic dermatitis.\n\n \n \n \n \n \n \n\n \nNektar's Chief Research & Development Officer, Jonathan Zalevsky, Ph.D., will be presenting the final Phase 1b data and unveiling the trial design for the Phase 2b study of REZPEG in patients with moderate to severe atopic dermatitis. He will be joined by Nektar's Chief Medical Officer, Mary Tagliaferri, M.D., and by leading dermatology experts, including:\nDr. Jonathan Silverberg, Professor of Dermatology at The George Washington University School of Medicine and Health Sciences and Director of Clinical Research and Contact Dermatitis;Dr. David Rosmarin, Chair of the Department of Dermatology at Indiana University and Kampen-Norins Scholar in Dermatology; and,Dr. Raj Chovatiya, Assistant Professor of Dermatology at the Northwestern University Feinberg School of Medicine.To access the conference call, please pre-register at Nektar Earnings Call Registration. All registrants will receive dial-in information and a PIN allowing them to access the live call.\nInvestors and analysts can also view slides and listen to the live audio webcast of the presentation here. The event will also be available for replay through October 13, 2023 on Nektar's website: www.nektar.com.\nAbout the Presenters\nDr. Jonathan Silverberg\nDr. Silverberg is Professor of Dermatology at The George Washington University School of Medicine and Health Sciences in Washington, DC. He is the Director of Clinical Research and Contact Dermatitis. Dr. Silverberg's area of clinical subspecialty is inflammatory skin disease, particularly atopic and contact dermatitis. Dr. Silverberg has also been a local, national and/or international principal investigator for numerous clinical trials for novel treatments in atopic dermatitis and other inflammatory disorders. Dr. Silverberg's research interests include drug development, clinical trial design, ...